Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asit Parikh

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Tropical Gastroenterology : Official Journal of the Digestive Diseases Foundation|September 19, 2009
Clinical research boom in India: opportunism or opportunity?Asit Parikh
Inflammatory Bowel Diseases|February 4, 2010
Response to Baumgart reviewBrian G Feagan, Asit Parikh,
Journal of Neuroimmunology|September 27, 2013
Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotypeCatherine Milch, Tim Wyant, Jing Xu, et al.
Inflammatory Bowel Diseases|April 18, 2013
Long-term clinical experience with vedolizumab in patients with inflammatory bowel diseaseAsit Parikh, Irving Fox, Timothy Leach, et al.
Clinical Pharmacokinetics|May 20, 2017
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of VedolizumabMaria Rosario, Nathanael L Dirks, Catherine Milch, et al.
Clinical Drug Investigation|July 17, 2016
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy VolunteersMaria Rosario, Timothy Wyant, Timothy Leach, et al.
Gut|April 26, 2014
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial resultsTim Wyant, Tim Leach, Serap Sankoh, et al.
The American Journal of Gastroenterology|July 4, 2014
Comment on 'anti-adhesion therapies and the rule of 3 for rare events'Brian G Feagan, Jean-Frederic Colombel, Stephen B Hanauer, et al.
Inflammatory Bowel Diseases|December 8, 2011
Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging studyAsit Parikh, Timothy Leach, Tim Wyant, et al.
Current Medical Research and Opinion|July 3, 2015
Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research DatabaseMegan E McAuliffe, Stephan Lanes, Timothy Leach, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Tropical Gastroenterology : Official Journal of the Digestive Diseases Foundation|September 19, 2009
Clinical research boom in India: opportunism or opportunity?Asit Parikh
Inflammatory Bowel Diseases|February 4, 2010
Response to Baumgart reviewBrian G Feagan, Asit Parikh,
Journal of Neuroimmunology|September 27, 2013
Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotypeCatherine Milch, Tim Wyant, Jing Xu, et al.
Inflammatory Bowel Diseases|April 18, 2013
Long-term clinical experience with vedolizumab in patients with inflammatory bowel diseaseAsit Parikh, Irving Fox, Timothy Leach, et al.
Clinical Pharmacokinetics|May 20, 2017
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of VedolizumabMaria Rosario, Nathanael L Dirks, Catherine Milch, et al.
Clinical Drug Investigation|July 17, 2016
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy VolunteersMaria Rosario, Timothy Wyant, Timothy Leach, et al.
Gut|April 26, 2014
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial resultsTim Wyant, Tim Leach, Serap Sankoh, et al.
The American Journal of Gastroenterology|July 4, 2014
Comment on 'anti-adhesion therapies and the rule of 3 for rare events'Brian G Feagan, Jean-Frederic Colombel, Stephen B Hanauer, et al.
Inflammatory Bowel Diseases|December 8, 2011
Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging studyAsit Parikh, Timothy Leach, Tim Wyant, et al.
Current Medical Research and Opinion|July 3, 2015
Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research DatabaseMegan E McAuliffe, Stephan Lanes, Timothy Leach, et al.
Pageof 3